相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Adalimumab and etanercept serum (anti)drug levels are not predictive for successful dose reduction or discontinuation in rheumatoid arthritis
Noortje van Herwaarden et al.
ANNALS OF THE RHEUMATIC DISEASES (2015)
Immunogenicity assessment of biotherapeutic products: An overview of assays and their utility
Meenu Wadhwa et al.
BIOLOGICALS (2015)
Therapeutic outcomes, assessments, risk factors and mitigation efforts of immunogenicity of therapeutic protein products
Liusong Yin et al.
CELLULAR IMMUNOLOGY (2015)
Standardizing terms, definitions and concepts for describing and interpreting unwanted immunogenicity of biopharmaceuticals: recommendations of the Innovative Medicines Initiative ABIRISK consortium
B. Rup et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2015)
Systematic comparison of drug-tolerant assays for anti-drug antibodies in a cohort of adalimumab-treated rheumatoid arthritis patients
Karien Bloem et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2015)
Comparative immunogenicity assessment: a critical consideration for biosimilar development
Patrick M. Liu et al.
BIOANALYSIS (2015)
Methodology to study polymers interaction by surface plasmon resonance imaging
N. Vollmer et al.
METHODSX (2015)
Assessment and Reporting of the Clinical Immunogenicity of Therapeutic Proteins and Peptides-Harmonized Terminology and Tactical Recommendations
G. Shankar et al.
AAPS JOURNAL (2014)
The use of biosimilars in immune-mediated disease: A joint Italian Society of Rheumatology (SIR), Italian Society of Dermatology (SIDeMaST), and Italian Group of Inflammatory Bowel Disease (IG-IBD) position paper
Gionata Fiorino et al.
AUTOIMMUNITY REVIEWS (2014)
Clinical investigation in highly disease-affected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evaluation: the CHANGE study
Nobuyuki Miyasaka et al.
Modern Rheumatology (2014)
Regulatory and clinical considerations for biosimilar oncology drugs
Charles L. Bennett et al.
LANCET ONCOLOGY (2014)
Biosimilar medicines - their use in the treatment of inflammatory bowel diseases. Position statement of the Working Group of the Polish National Consultant in Gastroenterology
Aldona Mularczyk et al.
PRZEGLAD GASTROENTEROLOGICZNY (2014)
Anti-tumor necrosis factor patent expiration and the risks of biocopies in clinical practice
Morton Scheinberg et al.
ARTHRITIS RESEARCH & THERAPY (2014)
Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective
Fabien B. Vincent et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Long-term measurement of anti-adalimumab using pH-shift-anti-idiotype antigen binding test shows predictive value and transient antibody formation
Pauline A. van Schouwenburg et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Peri-Infusional Adverse Reactions to Rituximab in Patients with Non-Hodgkin's Lymphoma
Teresa Arredondo-Garza et al.
ARCHIVES OF MEDICAL RESEARCH (2013)
Joint position statement by "Sociedad Española de Patología Digestiva" (Spanish Society of Gastroenterology) and "Sociedad Española de Farmacología" (Spanish Society of Pharmacology) on biosimilar therapy for inflammatory bowel disease
Federico Argüelles-Arias et al.
REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS (2013)
Assessing immunogenicity of biosimilar therapeutic monoclonal antibodies: regulatory and bioanalytical considerations
Paul Chamberlain
BIOANALYSIS (2013)
Biosimilar drugs in Mexico: Position of the Mexican College of Rheumatology, 2012
Rolando Espinosa Morales et al.
REUMATOLOGIA CLINICA (2013)
Biosimilars and biobetters as tools for understanding and mitigating the immunogenicity of biotherapeutics
Maria D. F. S. Barbosa et al.
DRUG DISCOVERY TODAY (2012)
Anti-TNF-α biotherapies: perspectives for evidence-based personalized medicine
Klaus Bendtzen
IMMUNOTHERAPY (2012)
Development and validation of a homogeneous mobility shift assay for the measurement of infliximab and antibodies-to-infliximab levels in patient serum
Shui-Long Wang et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2012)
Interchangeability, immunogenicity and biosimilars
Hans C. Ebbers et al.
NATURE BIOTECHNOLOGY (2012)
Challenges of developing and validating immunogenicity assays to support comparability studies for biosimilar drug development
Xiao-Yan Cai et al.
BIOANALYSIS (2012)
On the Regulatory Approval Pathway of Biosimilar Products
Jun Wang et al.
PHARMACEUTICALS (2012)
Taking immunogenicity assessment of therapeutic proteins to the next level
I. C. Buettel et al.
BIOLOGICALS (2011)
Key concepts and critical issues on epoetin and filgrastim biosimilars. A position paper from the Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation
Giovanni Barosi et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
Development of Antidrug Antibodies Against Adalimumab and Association With Disease Activity and Treatment Failure During Long-term Follow-up
Geertje M. Bartelds et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
Differential effect of drug interference in immunogenicity assays
Margreet H. Hart et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2011)
Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis
Dora Pascual-Salcedo et al.
RHEUMATOLOGY (2011)
Immunogenicity of therapeutics: a matter of efficacy and safety
Andreas Nechansky et al.
EXPERT OPINION ON DRUG DISCOVERY (2010)
A novel method for the detection of antibodies to adalimumab in the presence of drug reveals hidden immunogenicity in rheumatoid arthritis patients
Pauline A. van Schouwenburg et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2010)
Biopharmaceutical benchmarks 2010
Gary Walsh
NATURE BIOTECHNOLOGY (2010)
Surprising negative association between IgG1 allotype disparity and anti-adalimumab formation: a cohort study
Geertje M. Bartelds et al.
ARTHRITIS RESEARCH & THERAPY (2010)
Immunogenicity of rituximab in patients with severe pemphigus
Enno Schmidt et al.
CLINICAL IMMUNOLOGY (2009)
Dealing with immunogenicity of biologicals: assessment and clinical relevance
Gerrit J. Wolbink et al.
CURRENT OPINION IN RHEUMATOLOGY (2009)
How to systematically evaluate immunogenicity of therapeutic proteins - regulatory considerations
Eva-Maria Jahn et al.
NEW BIOTECHNOLOGY (2009)
Immunogenicity of anti-tumor necrosis factor antibodies - toward improved methods of anti-antibody measurement
Lucien Aarden et al.
CURRENT OPINION IN IMMUNOLOGY (2008)
Improvement of drug tolerance in immunogenicity testing by acid treatment on Biacore
Denise Sickert et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2008)
Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products
Eugen Koren et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2008)
Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products
Gopi Shankar et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2008)
An affinity capture elution (ACE) assay for detection of anti-drug antibody to monoclonal antibody therapeutics in the presence of high levels of drug
James S. Bourdage et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2007)
Immunogenicity of protein therapeutics and the interplay between tolerance and antibody responses
Mario D. F. S. Borbosa et al.
DRUG DISCOVERY TODAY (2007)
Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis
Geertje M. Bartelds et al.
ANNALS OF THE RHEUMATIC DISEASES (2007)
A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs
Gopi Shankar et al.
NATURE BIOTECHNOLOGY (2007)
Recommendations for the design, optimization, and qualification of cell-based assays used for the detection of neutralizing antibody responses elicited to biological therapeutics
Shalini Gupta et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2007)
Opinion - The FDA's assessment of follow-on protein products: a historical perspective
Janet Woodcock et al.
NATURE REVIEWS DRUG DISCOVERY (2007)
An acid dissociation bridging ELISA for detection of antibodies directed against therapeutic proteins in the presence of antigen
A Patton et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2005)
Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy - A randomized, placebo-controlled, 52-week trial
EC Keystone et al.
ARTHRITIS AND RHEUMATISM (2004)
Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products
AR Mire-Sluis et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2004)
Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed
BA van de Putte et al.
ANNALS OF THE RHEUMATIC DISEASES (2004)
Strategies for detection, measurement and characterization of unwanted antibodies induced by therapeutic biologicals
M Wadhwa et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2003)
Adalimumab, a fully human anti-tumor necrosis factor a monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate - The ARMADA trial
ME Weinblatt et al.
ARTHRITIS AND RHEUMATISM (2003)
Immunogenicity of therapeutic proteins: Clinical implications and future prospects
H Schellekens
CLINICAL THERAPEUTICS (2002)
Bioequivalence and the immunogenicity of biopharmaceuticals
H Schellekens
NATURE REVIEWS DRUG DISCOVERY (2002)
Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin.
N Casadevall et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Thrombocytopenia caused by the development of antibodies to thrombopoietin
JZ Li et al.
BLOOD (2001)
分享论文
